Innovation Medical Management (002173) Fundamentals 2026 — Revenue Analysis | SniperIQ
Innovation Medical Management (002173) is a CN-listed Consumer Cyclical company in Luxury Goods with a market capitalization of ¥7.5B, trading at ¥17.05 on the SHZ. This SniperIQ fundamentals page covers Innovation Medical Management's valuation, profitability (net margin -7.3%), revenue (¥781M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Innovation Medical Management's market cap?
Innovation Medical Management (002173) has a market capitalization of approximately ¥7.5B, trading at ¥17.05 on the SHZ. Market cap moves with the live share price.
What is Innovation Medical Management's P/E ratio?
Innovation Medical Management's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.1x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.
How profitable is Innovation Medical Management?
Innovation Medical Management runs a net profit margin of -7.3%, a gross margin of 3.8%, and an operating margin of -12.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Innovation Medical Management generate?
Innovation Medical Management reported revenue of ¥781M for fiscal year 2025, with net income of -¥35M and earnings per share (EPS) of -0.079. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Innovation Medical Management pay a dividend?
Innovation Medical Management does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Innovation Medical Management financially healthy?
Innovation Medical Management carries a debt-to-equity ratio of 0.04x and a current ratio of 1.85x, with a market beta of 0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Innovation Medical Management a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Innovation Medical Management (002173) the key facts are: market cap ¥7.5B, revenue ¥781M, 52-week range 14.07-38.31. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.
Track Innovation Medical Management's full fundamentals live
Get Innovation Medical Management's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.